Telehealth  Virtual Visits Market in US
Healthcare TB

Tumor Necrosis Factor Alpha (TNF-a) Inhibitors-Pipeline Insights 2017

Date: July 2017   Number of Pages: 70 
Geography:  Global Delivery Timeline: 6-7 Business Days

 

StumbleUponEmail
SKU: HPA1707-01 Categories: ,

Product Description

Tumor Necrosis Factor Alpha (TNF-a) inhibitors represent a major treatment paradigm for inflammatory diseases. Anti TNF-a drug class, is one of the most commercially successful drug classes in the pharmaceutical industry worldwide. Currently, marketed anti-TNF-a drugs are among the top five global block buster drugs. The cumulative sale of the leading three TNF-a inhibitors (Remicade, Enbrel, Humira) surpassed $32 billion in 2016.

TNF-a inhibitors exhibit therapeutic efficacy as they block activities of the tumor necrosis factor (TNF), a cytokine, which causes inflammation and leads to diverse immune-system diseases. Apparently, almost all the currently marketed TNF-a drugs are indicated for a wide spectrum of immune-related disorders such as – Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and uveitis. Advancement in biological research is discovering advanced therapeutic benefits of this drug class for wider indications. Currently, clinical research is focused on evaluating therapeutic efficacy and safety of TNF-a inhibitors on a wide range of inflammatory diseases, neurodegenerative diseases, and multiple cancers.

Scope Of The Report

The report:

  • Provides in-depth insights about active tumor necrosis factor alpha (TNF-a) inhibitors pipeline drug candidates
  • Offers an extensive pipeline product coverage with demarcation by various stages of development from NDA filings to discovery
  • Provides pipeline assessment by monotherapy, combination therapy products, and route of administration
  • Provides comparative analysis of key marketed and pipeline TNF-a inhibitors
  • Includes coverage of detailed pipeline drug profiles, which include product description, chemical information, MOA, licensors and collaborators, development sectionner
  • Analyzes key players involved in clinical research and development of the TNF-a inhibitors
  • Provides the coverage of key news related to TNF-a inhibitors, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates

Why Should You Buy The Report?

  • To gain erudite insights about the TNF-a inhibitor pipeline landscape
  • To ascertain unique product development dynamics and leverage it for new target identification, drug repositioning, and precision medicine
  • To optimize the pipeline product portfolio in correspondence with the dynamic pharmaceutical market
  • To identify competitors and design strategic initiatives for drug development activities
  • To understand the market and choose right sectionners for strategic collaborations
  • To obtain informed updates on drug termination/drug discontinuation

The “Tumor Necrosis Factor Alpha (TNF-a) Inhibitors-Pipeline Insights2017″ report provides a comprehensive analysis of TNF-a drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential TNF-a inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trialdata along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and EMA designations. It also assesses the pipeline TNF-a inhibitors by monotherapy, combination products, molecule type and route of administration. In addition to analysis on active pipeline molecules, the report also provides a detailed information about discontinued and dormant drugs.

The report profiles key players in developing potential TNF-a drug candidates. The company profile section provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.

SECTION 1: Executive Summary
SECTION 2: Scope of the Report
SECTION 3: Introduction
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors – Overview
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors –Associated Diseases
SECTION 4: Tumor Necrosis Factor (TNF) Inhibitors – Pipeline Landscape
  • Overview of Pipeline Tumor Necrosis Factor-alpha (TNF-a)
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors Filed and Phase III Products
  • Comparative Analysis 
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors Phase II Products
  • Comparative Analysis 
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors Phase I and IND Filed Products
  • Comparative Analysis 
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors Discovery and Pre-Clinical Stage Products 
  • Comparative Analysis 
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors – Discontinued Products 
  • Tumor Necrosis Factor-alpha (TNF-a) Inhibitors – Dormant Products
SECTION 5: Tumor Necrosis Factor-alpha (TNF-a) Inhibitors – Therapeutics Assessment (Pipeline)
  • Assessment by Monotherapy Products 
  • Assessment by Combination Products 
  • Assessment by Route of Administration 
SECTION 6: Comparative Analysis of Marketed and Pipeline Tumor Necrosis Factor (TNF-a) Inhibitors
SECTION 7: Key Pipeline Product Profiles
SECTION 8: Competitive Landscape
  • Key Company Profiles
SECTION 9: Key News
  • Major Mergers and Acquisitions
  • Product News (including clinical trial progression updates)
List of Tables
• Pipeline Tumor Necrosis Factor-alpha (TNF-a) Inhibitor Drug Candidates by Therapy Area 2017
• Comparative Analysis by Filed and Phase III Products 2017
• Comparative Analysis Phase II Products 2017
• Comparative Analysis Phase I and IND Filed Products 2017
• Comparative Analysis Discovery and Pre-Clinical Stage Products 2017
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors – Discontinued Products 
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors – Dormant Products
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors Assessment by Monotherapy Products 
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors Assessment by Combination Products 
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors Assessment by Route of Administration 
• Comparative Analysis Marketed and Pipeline Tumor Necrosis Factor Alpha (TNF-a) Inhibitors
• Drug Candidates Profiles
 
List of Figures
 
• Pipeline Anti-TNF-a Inhibitor Drug Candidates by Therapy Area 2017
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors – Filed and Phase III Products 2017
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors – Phase II Products 2017
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors – Phase I and IND Filed Products 2017
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors – Discovery and Pre-Clinical Stage Products 2017
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors Assessment by Monotherapy Products 
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors Assessment by Combination Products 
• Tumor Necrosis Factor Alpha (TNF-a) Inhibitors Assessment by Route of Administration 

 





Reviews

There are no reviews yet.

Be the first to review “Tumor Necrosis Factor Alpha (TNF-a) Inhibitors-Pipeline Insights 2017”

Request Call Back
Request Call Back
Need Custom Report?
click here

Our Services

  • Beige Market Intelligence - Syndicated Research Reports

  • Beige Market Intelligence - Market Research and Custom Research

  • Beige Market Intelligence - Business Consulting